دورية أكاديمية
Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL).
| العنوان: | Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL). |
|---|---|
| المؤلفون: | Leclercq, I, Mortreux, F, Morschhauser, F, Duthilleul, P, Desgranges, C, Gessain, A, Cavrois, M, Vernant, J. P., Hermine, O, Wattel, E |
| المساهمون: | Cellule d'Intervention Biologique d'Urgence - Laboratory for Urgent Response to Biological Threats (CIBU), Institut Pasteur Paris (IP), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Biologie Moléculaire de la Cellule (LBMC), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'hématologie, Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Departement d'Hematologie, Immunologie et Cytogenetique, Centre Hospitalier, Adaptation cardiovasculaire à l'ischemie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et Physiopathologie des Virus Oncogènes (EPVO (UMR_3569 / U-Pasteur_3)), Institut Pasteur Paris (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Génétique moléculaire et approches thérapeutiques des hémopathies malignes, IRCL-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), manuscript. This work was supported by grants from the Association pour la Recherche sur le Cancer, from the Fe´de´ration Nationale des Groupements des Entreprises Franc¸aises dans la Lutte contre le Cancer (FEGEFLUC) and from the Ligue Nationale contre le Cancer (Comite´ Pas de Calais). I.L. and F.M. were supported by bursaries from the Ministe`re de l'Enseignement Supe´rieur et de la Recherche. We thank Isabelle Allard, Aspasia Stamatoullas, Anne- Chantal Braud, Fre´deric Viret and Dominique Jaubert for a number of samples from ATLL patients. We also thank Professor Wattre and collaborators who kindly allowed us to use their laboratories for DNA extraction, digestion, ligation and PCR. |
| المصدر: | ISSN: 0007-1048. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 1999 |
| المجموعة: | Université de Lyon: HAL |
| مصطلحات موضوعية: | Acute, Leukemia, Lymphocytic, Middle Aged, Male, L2/*pathology/therapy, Adult, Bone Marrow Transplantation, Clone Cells, Female, HIV Seropositivity, Human T-lymphotropic virus 1, Humans, Neoplasm, Residual, Polymerase Chain Reaction/methods, Research Support, Non-U.S. Gov't, OCIS 000.1430, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology |
| الوصف: | International audience ; Many adult T-cell leukaemia/lymphoma (ATLL) patients who respond to induction treatment, then relapse. Knowing the clonality pattern of residual tumourous clones during treatment could help understand disease evolution and aid therapeutic decisions. We developed a sensitive and semi-quantitative molecular analysis of these clones in ATLL patients. DNA samples from PBMCs derived from eight ATLL patients were studied over time by quadruplicate linker mediated PCR (LMPCR) amplification of HTLV-1 integration sites. Patients were treated with combination chemotherapy, zidovudine-interferon-alpha and/or by peripheral stem cell transplantation or allogeneic bone marrow transplantation. Persistence of tumourous clones at a high frequency (>1/300 PBMCs) was frequently observed, even in complete responders, and was invariably correlated with relapse and/or poor outcome. Fluctuation in the frequency of some tumourous clones was observed with evidence for clonal change under treatment in one patient, indicating that treatment of ATLL can result in the selection of resistant clones. Finally, allogeneic bone marrow transplantation (BMT) using an HTLV-1 infected sibling as donor was found to be associated with long-lasting disappearance of tumourous clones and a possible cure of the disease. Long-term persistent clonal expansion of circulating HTLV-1 bearing T cells which derived from the donor bone marrow was evidenced in this patient. In conclusion, variable success in treatment of ATLL is probably due to the clonal heterogeneity which results in the selection of resistant clones. Semi-quantitative assessment of residual disease (RD) through LMPCR may predict treatment failure. Accordingly, additional therapy may be tailored to the clonality pattern observed after first-line therapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/10354140; hal-00115833; https://hal.science/hal-00115833Test; PRODINRA: 318637; PUBMED: 10354140 |
| DOI: | 10.1046/j.1365-2141.1999.01389.x |
| الإتاحة: | https://doi.org/10.1046/j.1365-2141.1999.01389.xTest https://hal.science/hal-00115833Test |
| رقم الانضمام: | edsbas.3AA7004B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1046/j.1365-2141.1999.01389.x |
|---|